Pyxis Oncology
PYXS
74 hedge funds and large institutions have $30.2M invested in Pyxis Oncology in 2025 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 20 increasing their positions, 24 reducing their positions, and 30 closing their positions.
700% more call options, than puts
Call options by funds: $16K | Put options by funds: $2K
2% more capital invested
Capital invested by funds: $29.6M → $30.2M (+$555K)
4.79% less ownership
Funds ownership: 49.12% → 44.32% (-4.8%)
17% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 24
17% less funds holding
Funds holding: 89 → 74 (-15)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.58M |
| 2 |
Millennium Management
New York
|
+$1.19M |
| 3 |
Jane Street
New York
|
+$379K |
| 4 |
SC
Schulhoff & Co
Cincinnati,
Ohio
|
+$172K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$166K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.64M |
| 2 |
State Street
Boston,
Massachusetts
|
-$841K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$674K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$601K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$324K |
PYXS Hedge Fund Activity: Q2 2025 in Review
74 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q2 2025, worth a combined $30.2M — up 1.9% from $29.6M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of PYXS and 15 opened new positions — a net loss of 15 holders — while 24 trimmed existing stakes and 20 added.
The largest buyer was Tang Capital Management, adding an estimated $1.58M. The largest seller was BlackRock, cutting an estimated $2.64M.
- 74 institutional investors held Pyxis Oncology (PYXS) as of Q2 2025, down from 89 in Q1 2025.
- Funds reported $30.2M of Pyxis Oncology stock for Q2 2025, up 1.9% quarter-over-quarter.
- 15 funds opened new Pyxis Oncology positions in Q2 2025 and 30 closed out, a net change of -15 holders.
- The largest Pyxis Oncology buyer in Q2 2025 was Tang Capital Management, an estimated $1.58M added.
- The largest Pyxis Oncology seller in Q2 2025 was BlackRock, an estimated $2.64M sold.
Based on aggregated 13F filings for Q2 2025.